These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 7919761

  • 1. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, Malvaux P, Fawe L, Bourguignon JP.
    Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
    [Abstract] [Full Text] [Related]

  • 2. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ, Hümmelink R, Peter M, Sippell WG, Oostdijk W, Odink RJ, Drop SL.
    Horm Res; 1993 Jun; 39(3-4):111-7. PubMed ID: 8262471
    [Abstract] [Full Text] [Related]

  • 3. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ, Hümmelink R, Sippell WG, Oostdijk W, Odink RJ, Drop SL.
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [Abstract] [Full Text] [Related]

  • 4. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
    Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, De Sanctis C, Rigon F, Zamboni G, Bernasconi S.
    Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
    [Abstract] [Full Text] [Related]

  • 5. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [Abstract] [Full Text] [Related]

  • 6. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y, Wei H, Zhang JL, Hou L, Luo XP.
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [Abstract] [Full Text] [Related]

  • 7. [Short-term comparison of the treatment of precocious puberty with 2 different LHRH antagonists (buserelin and long-acting triptorelin). An endocrinologic and echographic study].
    Cicognani A, Cacciari E, Balsamo A, Cassio A, Papasodero A, Bellizzi M, Guacci P, Zappulla F.
    Pediatr Med Chir; 1994 Nov; 16(1):43-8. PubMed ID: 8029088
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH.
    J Korean Med Sci; 2021 Aug 30; 36(34):e219. PubMed ID: 34463062
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty.
    Liang Y, Wei H, Zhang J, Hou L, Luo X.
    J Huazhong Univ Sci Technolog Med Sci; 2006 Aug 30; 26(5):558-61. PubMed ID: 17219967
    [Abstract] [Full Text] [Related]

  • 10. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).
    Bourguignon JP, Van Vliet G, Vandeweghe M, Malvaux P, Vanderschueren-Lodeweyckx M, Craen M, Du Caju MV, Ernould C.
    Eur J Pediatr; 1987 Nov 30; 146(6):555-60. PubMed ID: 3123239
    [Abstract] [Full Text] [Related]

  • 11. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M, Di Maio S, Gasparini N, Mariano A, Macchia V, Tenore A.
    Horm Res; 1998 Nov 30; 50(4):205-11. PubMed ID: 9838241
    [Abstract] [Full Text] [Related]

  • 12. More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children.
    Wide L, Albertsson-Wikland K, Phillips DJ.
    J Clin Endocrinol Metab; 1996 Jan 30; 81(1):216-21. PubMed ID: 8550754
    [Abstract] [Full Text] [Related]

  • 13. Evaluation and significance of the degree of pituitary-gonadal inhibition during intranasal administration of buserelin.
    Bourguignon JP, Heinrichs C, Van Vliet G, Vandeweghe M, Vanderschueren-Lodeweyckx M, Malvaux P, Du Caju M, Craen M, Lambrechts L, Delire M.
    Acta Endocrinol (Copenh); 1987 Dec 30; 116(4):519-25. PubMed ID: 3122484
    [Abstract] [Full Text] [Related]

  • 14. Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment.
    Tatò L, Saggese G, Cavallo L, Antoniazzi F, Corrias A, Pasquino AM, Cisternino M.
    Horm Res; 1995 Dec 30; 44 Suppl 3():49-54. PubMed ID: 8719441
    [Abstract] [Full Text] [Related]

  • 15. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
    Antoniazzi F, Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Borrelli P, Osio D, Mengarda F, De Luca F, Tatò L.
    J Pediatr Endocrinol Metab; 2000 Jul 30; 13 Suppl 1():773-80. PubMed ID: 10969920
    [Abstract] [Full Text] [Related]

  • 16. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues.
    Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G.
    Eur J Pediatr; 2000 May 30; 159(5):369-74. PubMed ID: 10834524
    [Abstract] [Full Text] [Related]

  • 17. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
    Luder AS, Holland FJ, Costigan DC, Jenner MR, Wielgosz G, Fazekas AT.
    J Clin Endocrinol Metab; 1984 Jun 30; 58(6):966-72. PubMed ID: 6427266
    [Abstract] [Full Text] [Related]

  • 18. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N, Triptorelin 3-month CPP Study Group.
    Eur J Endocrinol; 2006 Jan 30; 154(1):119-24. PubMed ID: 16382000
    [Abstract] [Full Text] [Related]

  • 19. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F.
    J Clin Endocrinol Metab; 1999 Feb 30; 84(2):449-52. PubMed ID: 10022399
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, Linares J, Lundström E, Purcea D, Cassorla F.
    J Pediatr Endocrinol Metab; 2016 Nov 01; 29(11):1241-1248. PubMed ID: 26887034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.